{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:11:48Z","timestamp":1779207108528,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Correction of iron deficiency (ID) with intravenous iron among patients with heart failure (HF) may improve outcomes but is rarely assessed in real-world studies. Hospital admission for decompensated HF presents an opportunity to identify patients for treatment of ID. Of 2,275 patient admissions for decompensated HF, iron studies were available for 526 (23.1%) and ID was identified in 332 (63.1%) patients. Iron replacement was oral in 241 (10.6%) or intravenous in 285 (12.5%) with 132 (46.3%) patients receiving treatment during the admission. Anemia, chronic kidney disease stage 3 (CKD3), and low mean corpuscular volume (MCV) were associated with a higher odds of iron study availability while age was associated with lower odds. Frequency of assessment of ID in HF patients remains low. Predictors of iron status assessment indicate that factors related to anemia rather than HF are likely responsible for iron status assessment among these patients.<\/jats:p>","DOI":"10.1007\/s12265-026-10774-8","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:28:10Z","timestamp":1779204490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Iron Deficiency Screening in Patients Admitted with Acute Heart Failure Decompensation"],"prefix":"10.1007","volume":"19","author":[{"given":"Alex M.","family":"Sindledecker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yassar","family":"Nabeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence A.","family":"Frazee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"4","key":"10774_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure. J Card Fail. 2021;27(4):387\u2013413. https:\/\/doi.org\/10.1016\/j.cardfail.2021.01.022.","journal-title":"J Card Fail"},{"key":"10774_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijcard.2018.03.024","volume":"261","author":"N Olchanski","year":"2018","unstructured":"Olchanski N, Vest AR, Cohen JT, Neumann PJ, DeNofrio D. Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissions. Int J Cardiol. 2018;261:103\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2018.03.024.","journal-title":"Int J Cardiol"},{"issue":"3","key":"10774_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cardfail.2021.12.017","volume":"28","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Fonarow GC, Opsha Y, Sandhu AT, Sweitzer NK, Warraich HJ. Economic Issues in Heart Failure in the United States. J Card Fail. 2022;28(3):453\u201366. https:\/\/doi.org\/10.1016\/j.cardfail.2021.12.017.","journal-title":"J Card Fail"},{"issue":"4","key":"10774_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.mjafi.2022.04.013","volume":"78","author":"B Singh","year":"2022","unstructured":"Singh B, Bajaj N, Singh P, Kumar Ghosh A, Anathakrishnan R, Singh N. Iron deficiency in patients of heart failure with reduced ejection fraction. Med J Armed Forces India. 2022;78(4):463\u20138. https:\/\/doi.org\/10.1016\/j.mjafi.2022.04.013.","journal-title":"Med J Armed Forces India"},{"issue":"11","key":"10774_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","volume":"389","author":"J Mentz Robert","year":"2023","unstructured":"Mentz Robert J, Jyotsna G, Rockhold Frank W, et al. Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med. 2023;389(11):975\u201386. https:\/\/doi.org\/10.1056\/NEJMoa2304968.","journal-title":"N Engl J Med"},{"key":"10774_CR6","doi-asserted-by":"publisher","unstructured":"Amaechi UM, Aiwuyo HO, Ewelukwa C et al. Assessing iron status in chronic heart failure patients by using serum ferritin and transferrin saturation levels: a cross-sectional descriptive study. Cureus 15(5):e39425. https:\/\/doi.org\/10.7759\/cureus.39425","DOI":"10.7759\/cureus.39425"},{"issue":"5","key":"10774_CR7","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/ehf2.12797","volume":"7","author":"VK Chopra","year":"2020","unstructured":"Chopra VK, Anker SD. Anaemia, iron deficiency and heart failure in 2020: facts and numbers. ESC Heart Fail. 2020;7(5):2007\u201311. https:\/\/doi.org\/10.1002\/ehf2.12797.","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10774_CR8","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/ehf2.13265","volume":"8","author":"G Loncar","year":"2021","unstructured":"Loncar G, Obradovic D, Thiele H, von Haehling S, Lainscak M. Iron deficiency in heart failure. ESC Heart Fail. 2021;8(4):2368\u201379. https:\/\/doi.org\/10.1002\/ehf2.13265.","journal-title":"ESC Heart Fail"},{"issue":"19","key":"10774_CR9","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1001\/jama.2017.5427","volume":"317","author":"GD Lewis","year":"2017","unstructured":"Lewis GD, Malhotra R, Hernandez AF, et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA. 2017;317(19):1958\u201366. https:\/\/doi.org\/10.1001\/jama.2017.5427.","journal-title":"JAMA"},{"issue":"25","key":"10774_CR10","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Colet JC, Filippatos G, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med. 2009;361(25):2436\u201348. https:\/\/doi.org\/10.1056\/NEJMoa0908355.","journal-title":"N Engl J Med"},{"issue":"10266","key":"10774_CR11","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet Lond Engl. 2020;396(10266):1895\u2013904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4.","journal-title":"Lancet Lond Engl"},{"issue":"15","key":"10774_CR12","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","volume":"136","author":"DJ van Veldhuisen","year":"2017","unstructured":"van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation. 2017;136(15):1374\u201383. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.027497.","journal-title":"Circulation"},{"issue":"11","key":"10774_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020. Eur Heart J. 2015;36(11):657\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehu385.","journal-title":"Eur Heart J"},{"issue":"10369","key":"10774_CR14","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199\u2013209. https:\/\/doi.org\/10.1016\/S0140-6736(22)02083-9.","journal-title":"Lancet"},{"key":"10774_CR15","doi-asserted-by":"publisher","unstructured":"Anker SD, Friede T, Butler J, et al. Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2 DZHK05 randomized clinical trial. JAMA Published online March. 2025;30. https:\/\/doi.org\/10.1001\/jama.2025.3833.","DOI":"10.1001\/jama.2025.3833"},{"issue":"7","key":"10774_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/ejhf.473","volume":"18","author":"EA Jankowska","year":"2016","unstructured":"Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18(7):786\u201395. https:\/\/doi.org\/10.1002\/ejhf.473.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10774_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ejhf.823","volume":"20","author":"SD Anker","year":"2018","unstructured":"Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125\u201333. https:\/\/doi.org\/10.1002\/ejhf.823.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10774_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/ejhf.2860","volume":"25","author":"SD Anker","year":"2023","unstructured":"Anker SD, Khan MS, Butler J, et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis. Eur J Heart Fail. 2023;25(7):1080\u201390. https:\/\/doi.org\/10.1002\/ejhf.2860.","journal-title":"Eur J Heart Fail"},{"key":"10774_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-025-03671-1","volume":"30","author":"SD Anker","year":"2025","unstructured":"Anker SD, Karakas M, Mentz RJ, et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med Published online March. 2025;30:1\u20131. https:\/\/doi.org\/10.1038\/s41591-025-03671-1.","journal-title":"Nat Med Published online March"},{"key":"10774_CR20","doi-asserted-by":"publisher","unstructured":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","DOI":"10.1161\/CIR.0000000000001063"},{"key":"10774_CR21","doi-asserted-by":"publisher","unstructured":"Baljash Cheema MD, Anuj Chokshi MD, Olusola Orimoloye MD, Hossein Ardehali MD. Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency: JACC State-of-the-Art Review. J Am Coll Cardiol Published online June. 2024;25. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.431.","DOI":"10.1016\/j.jacc.2024.03.431"},{"key":"10774_CR22","unstructured":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure."},{"issue":"2","key":"10774_CR23","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/ehf2.13850","volume":"9","author":"A Cohen-Solal","year":"2022","unstructured":"Cohen-Solal A, Philip J, Picard F, et al. Iron deficiency in heart failure patients: the French CARENFER prospective study. ESC Heart Fail. 2022;9(2):874\u201384. https:\/\/doi.org\/10.1002\/ehf2.13850.","journal-title":"ESC Heart Fail"},{"issue":"Suppl1","key":"10774_CR24","doi-asserted-by":"publisher","first-page":"A18454","DOI":"10.1161\/circ.148.suppl_1.18454","volume":"148","author":"A Minasian","year":"2023","unstructured":"Minasian A, Griskowitz C, Prasad C, et al. Abstract 18454: Temporal Trends in Assessment and Management of Iron Status in Patients With Heart Failure: A Multi-Institutional Study. Circulation. 2023;148(Suppl1):A18454\u201318454. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.18454.","journal-title":"Circulation"},{"issue":"8","key":"10774_CR25","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/ejhf.2879","volume":"25","author":"F Lindberg","year":"2023","unstructured":"Lindberg F, Lund LH, Benson L, et al. Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project. Eur J Heart Fail. 2023;25(8):1270\u201380. https:\/\/doi.org\/10.1002\/ejhf.2879.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10774_CR26","doi-asserted-by":"publisher","first-page":"e004519","DOI":"10.1161\/CIRCHEARTFAILURE.117.004519","volume":"11","author":"N Grote Beverborg","year":"2018","unstructured":"Grote Beverborg N, Klip IT, Meijers WC, et al. Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. Circ Heart Fail. 2018;11(2):e004519. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004519.","journal-title":"Circ Heart Fail"},{"key":"10774_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clnesp.2020.07.008","volume":"39","author":"JR Gentil","year":"2020","unstructured":"Gentil JR, de Fabricio S, Tanaka CG. Should we use ferritin in the diagnostic criteria of iron deficiency in heart failure patients? Clin Nutr ESPEN. 2020;39:119\u201323. https:\/\/doi.org\/10.1016\/j.clnesp.2020.07.008.","journal-title":"Clin Nutr ESPEN"},{"issue":"4","key":"10774_CR28","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/joim.13503","volume":"292","author":"P Cacoub","year":"2022","unstructured":"Cacoub P, Choukroun G, Cohen-Solal A, et al. Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action. J Intern Med. 2022;292(4):542\u201356. https:\/\/doi.org\/10.1111\/joim.13503.","journal-title":"J Intern Med"},{"issue":"16","key":"10774_CR29","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/eurheartj\/ehae086","volume":"45","author":"JGF Cleland","year":"2024","unstructured":"Cleland JGF, Kalra PA, Pellicori P, et al. Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. Eur Heart J. 2024;45(16):1410\u201326. https:\/\/doi.org\/10.1093\/eurheartj\/ehae086.","journal-title":"Eur Heart J"},{"issue":"5","key":"10774_CR30","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3390\/nu14051039","volume":"14","author":"P Cacoub","year":"2022","unstructured":"Cacoub P, Choukroun G, Cohen-Solal A, et al. Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases. Nutrients. 2022;14(5):1039. https:\/\/doi.org\/10.3390\/nu14051039.","journal-title":"Nutrients"},{"issue":"2","key":"10774_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/CIRCULATIONAHA.124.068883","volume":"150","author":"M Packer","year":"2024","unstructured":"Packer M, Anker SD, Butler J, et al. Redefining Iron Deficiency in Patients With Chronic Heart Failure. Circulation. 2024;150(2):151\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.068883.","journal-title":"Circulation"},{"key":"10774_CR32","doi-asserted-by":"publisher","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27). https:\/\/doi.org\/10.1093\/eurheartj\/ehw128.","DOI":"10.1093\/eurheartj\/ehw128"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10774-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-026-10774-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10774-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:28:11Z","timestamp":1779204491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-026-10774-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10774"],"URL":"https:\/\/doi.org\/10.1007\/s12265-026-10774-8","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institution\u2019s IRB as an expedited study with minimal risk given the retrospective nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}},{"value":"Given the retrospective nature of this study, which poses no more than minimal risk, a waiver of informed consent was granted by the institution\u2019s IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The study team has no disclosures or conflicts of interest to note.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"54"}}